Rhochelle Krawetz

Rhochelle Krawetz is an Associate at Williams & Connolly LLP, specializing in patent litigation with a strong focus on the pharmaceutical and biotechnology sectors. Her practice primarily involves complex Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA) disputes, representing innovator pharmaceutical companies. Across all tracked appearances and public records, Ms. Krawetz consistently represents plaintiffs, particularly operating companies enforcing their patent rights.

Her notable case experience includes representing Regeneron Pharmaceuticals, Inc. as plaintiff in several high-stakes patent infringement actions. She was involved in Regeneron Pharmaceuticals, Inc. v. Formycon AG, Regeneron Pharmaceuticals, Inc. v. Celltrion, Inc., and Regeneron Pharmaceuticals, Inc. v. Sandoz Inc., as well as multidistrict litigation concerning Regeneron's EYLEA® (aflibercept) product. This includes Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc., where a district court granted a preliminary injunction in Regeneron's favor in June 2024, later resolved via a stipulation to vacate judgments and dismiss with prejudice in April 2025. She also contributed to Regeneron Pharmaceuticals, Inc. v. Amgen Inc., in which the Federal Circuit affirmed a denial of Regeneron's preliminary injunction motion in March 2025. While her litigation experience includes appeals at the Federal Circuit, there is no readily available information indicating regular appearances in PTAB or IPR proceedings.

Ms. Krawetz earned her J.D. from the University of Pennsylvania Carey School of Law in 2021, graduating magna cum laude and as a member of the Order of the Coif. She also holds an M.A.T. from Relay Graduate School of Education and a B.A. from The University of Chicago. Prior to joining Williams & Connolly, she served as a Law Clerk to Judge Timothy B. Dyk at the United States Court of Appeals for the Federal Circuit in 2022.